Vertex Pharmaceuticals (NasdaqGS:VRTX) reported strong Q4 results, reflecting continued execution on its broader portfolio ...

Vertex Flooring Presents High-Performance SPC Flooring Designed for Stability, Style, and Durability HOLLISTON, MA, ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) entered an agreement with WuXi Biologics to co-develop a trispecific T-cell Engager for B-cell mediated autoimmune diseases. The collaboration focuses on ...

Vertex Pharmaceuticals will soon try to commercialize another medicine. The new therapy targets the same market as four of its other products. Using a priority review voucher is an expensive choice, ...

Following over a year of slow uptake, Vertex Pharmaceuticals and CRISPR Therapeutics expect Casgevy revenues to nearly triple ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...

Biotech Vertex, known for its cystic fibrosis therapies, is set to report earnings on Feb. 12 ...

Vertex, Inc. (NASDAQ:VERX) Q4 2025 Earnings Call Transcript February 11, 2026 Vertex, Inc. misses on earnings expectations. Reported EPS is $ EPS, expectations were $0.17. Operator: Good day, and ...

(NASDAQ:VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today released its 2025 End‑of‑Year U.S. Sales Tax Rates and Rules Report. Tracking 12,414 U.S. tax ...

Switzerland-based CRISPR Therapeutics (CRSP) and Boston, Massachusetts-based Vertex (VRTX) have been collaborating together since signing an initial agreement in 2015, with Vertex paying CRISPR $75m ...

Total revenues of $666.8 million for the full year 2024, representing a 16.5% year-over-year increase, indicating strong business growth. Cloud revenues grew by 28.6% year-over-year for the full year ...